1959 related articles for article (PubMed ID: 11217867)
1. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
6. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
7. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1998 Jul; 14(1):97-133. PubMed ID: 10182198
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.
Fulton B; Goa KL
Drugs; 1997 Feb; 53(2):281-98. PubMed ID: 9028746
[TBL] [Abstract][Full Text] [Related]
9. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine: an atypical antipsychotic for schizophrenia.
Lund BC; Perry PJ
Expert Opin Pharmacother; 2000 Jan; 1(2):305-23. PubMed ID: 11249551
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Almond S; O'Donnell O
Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
Hamilton SH; Revicki DA; Edgell ET; Genduso LA; Tollefson G
Pharmacoeconomics; 1999 May; 15(5):469-80. PubMed ID: 10537964
[TBL] [Abstract][Full Text] [Related]
13. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
Edgell ET; Andersen SW; Johnstone BM; Dulisse B; Revicki D; Breier A
Pharmacoeconomics; 2000 Dec; 18(6):567-79. PubMed ID: 11227395
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
[TBL] [Abstract][Full Text] [Related]
18. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
[TBL] [Abstract][Full Text] [Related]
20. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Taylor DM; Wright T; Libretto SE;
J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
